Skip to main content
Premium Trial:

Request an Annual Quote

Battered by Weak Pharma Market, Qiagen Slashes Sales Outlook; Shares Plummet

Click here for an updated version of this article.


NEW YORK, July 3 - Qiagen today said a weak second quarter caused it to slash its sales targets for the year by 13 percent to around $300 million, and warned it may record just $350 million in sales next year.

The news triggered a flash-flood sell-off of Qiagen stock on the Nasdaq exchange, where shares fell nearly 38 percent, or $3.80, to $6.22, in mid-morning trade. The lowest the shares have traded over the past year before today's announcement was $10.01.

Qiagen complained in a statement that a marked slowdown in R&D spending by US drug companies battered its instrumentation and synthetic nucleic-acid business, and added that the straights were dire enough to affect sales and earnings for the rest of this year and 2003.

"What happened in the second quarter is that pharmaceutical revenues in the US, instead of growing rapidly, were actually flat or declined," Peer Schatz, Qiagen's chief financial officer, told Dow Jones Newswires. "This has got nothing to do with our products. We think there is a short-term contraction in pharmaceutical budgets."


He also told Dow Jones that the second-quarter developments will not alter the company's strategy.

Qiagen said it expects to make $.05 per share in the current second quarter, down from $.09 per share, and expects to make $.05 and $.06 per share for the third and fourth quarters, respectively. Qiagen's original projection was to earn $.11 per share for both periods.

Though next year should see a 48-percent jump in per-share earnings, to $.34, Qiagen said, that would still be significantly lower than the $.45 average forecasted by analysts up until this morning's statement.

Stressing a bright spot, Qiagen said that though instrumentation accounts for just 11 percent of its total worldwide sales, and that some 35 percent of its sales   are from the pharmaceutical industry, fully half of its total revenues come from academia, which remains a strong customer base.


Click here for more information.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.